83461-56-7
Chemical Structure
Mifamurtide
Synonym(s): MTP-PE; L-MTP-PE; CGP 19835
- CAS No.: 83461-56-7
- Formula:C59H109N6O19P
- Molecular Weight:1237.50
IUPAC Name: (2R)-3-(((((4R,5R,7R,10S,13R,18S)-13-carbamoyl-4-formyl-7,10,18-trimethyl-2,8,11,16,19-pentaoxo-5-((1R,2R)-1,2,3-trihydroxypropyl)-6-oxa-3,9,12,17,20-pentaazadocosan-22-yl)oxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl dipalmitate
InChIKey: ZVLWUMPAHCEZAW-KRNLDFAISA-N
SMILES: CCCCCCCCCCCCCCCC(OC[C@@H](OC(CCCCCCCCCCCCCCC)=O)COP(OCCNC([C@@H](NC(CC[C@@H](NC([C@@H](NC([C@H](O[C@]([C@H](O)[C@H](O)CO)([H])[C@@H](NC(C)=O)C=O)C)=O)C)=O)C(N)=O)=O)C)=O)(O)=O)=O
Biological Activity: Mifamurtide (MTP-PE), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide has potential for use in rare disease and osteosarcoma research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Mifamurtide | 99.58% | Mifamurtide (MTP-PE), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide is a specific ligand for NOD2 and acts as an insulin sensitizer. Mifamurtide has potential for use in rare disease and osteosarcoma research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Kevin Biteau, et al. L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. Am J Cancer Res. 2016 Feb 15;6(3):677-89. [Content Brief]
- [2]. Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine. Drugs R D, 2008. 9(2): p. 131-5. [Content Brief]
- [3]. Joseph F Cavallari, et al. Muramyl Dipeptide-Based Postbiotics Mitigate Obesity-Induced Insulin Resistance via IRF4. Cell Metab. 2017 May 2;25(5):1063-1074.e3. [Content Brief]
Keywords
